Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 3/20 | 0.40 |
| ▸ | RARA | P10276 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.37 |
| ▸ | PPARD | Q03181 | 9/20 | 0.37 |
| ▸ | PPARA | Q07869 | 6/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | RARG | P13631 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5961736 | 0.81 | LMNA (0.41) | CYP1A2MAPTCYP2C19PTPN11MEN1 | |
| SCHEMBL5961765 | 0.79 | NPC1 (0.45) | CYP1A2MAPTCYP2C19MEN1KMT2A | |
| SCHEMBL5961776 | 0.79 | THRB (0.37) | MAPTMEN1KMT2A | |
| SCHEMBL12738206 | 0.73 | RARB (0.44) | RARBRARACYP1A2MAPTCYP2C19 | |
| SCHEMBL20174162 | 0.73 | RARB (0.46) | RARBRARACYP1A2MAPTCYP2C19 | |
| SCHEMBL12738210 | 0.73 | RARB (0.44) | RARBRARACYP1A2MAPTCYP2C19 | |
| SCHEMBL12738208 | 0.73 | RARB (0.44) | RARBRARACYP1A2MAPTCYP2C19 | |
| SCHEMBL12738204 | 0.73 | RARB (0.44) | RARBRARACYP1A2MAPTCYP2C19 | |
| SCHEMBL5961740 | 0.72 | MAPT (0.43) | CYP1A2MAPTCYP2C19MEN1KMT2A | |
| SCHEMBL5961768 | 0.72 | LMNA (0.42) | CYP1A2MAPTCYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168734-B2 | Lateral alpha-substituted acrylate compound and polymer thereof | JNC CORPORATION (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20110144293-A1 | LATERAL ALPHA-SUBSTITUTED ACRYLATE COMPOUND AND POLYMER THEREOF | CHISSO CORPORATION (JP) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144293-A1 | LATERAL ALPHA-SUBSTITUTED ACRYLATE COMPOUND AND POLYMER THEREOF | LEF1, AFF1, CNKSR1 | RARB 228/4885RARA 128/4885CYP1A2 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.